Amneal Pharmaceuticals reported results for the quarter ended 2026 with revenue of $796.2M and diluted EPS of $0.18, versus $724.51M and $0.07 in the prior-year quarter, as net income rose to $57.66M from $22.42M a year earlier.Financial Highlights¹ Reported as “Net revenue”. ² Reported as “Net inc…
Amneal Pharmaceuticals entered into Amendment No. 3 to its Term Loan Credit Agreement to reprice its term loans and reduce borrowing costs. Consenting lenders converted $2.039 billion of existing term loans on a cashless basis, and the company added a $45.2 million term loan to prepay non-consentin…
Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The pending Kashiv acquisition will create a fully integrated biosimilar platform, while guidance for 2026 was raised across all key metrics.Based on Amneal Pharmace…
Q2 2026 saw 10% revenue growth and 12% adjusted EBITDA growth, driven by strong Specialty and Affordable Medicines performance and robust new product launches. Full-year 2026 guidance was raised across all key metrics, and the Kashiv acquisition is on track to expand biosimilar leadership.Original…
Pharmaceutical company Amneal Pharmaceuticals NASDAQ:AMRXwill be announcing earnings results this Thursday before market hours. Here’s what to expect.Amneal beat analysts’ revenue expectations last quarter, reporting revenues of $722.5 million, up 3.9% year on year. It was a strong quarter for the…
BRIDGEWATER, N.J., July 09, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. NASDAQ:AMRX (“Amneal” or the “Company”), today announced it will report second quarter 2026 financial results on Thursday, July 30, 2026, before market open. The Company will host an audio webcast at 8:30 a.m. ET.The…
